No Data
No Data
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Cuts Target Price to $40
Mizuho Securities analyst Uy Ear maintains $Cartesian Therapeutics(RNAC.US)$ with a buy rating, and adjusts the target price from $90 to $40.According to TipRanks data, the analyst has a success rate
Express News | Cartesian Therapeutics Inc : Mizuho Initiates With Buy Rating and $40 Price Target
Buy Rating Affirmed for Cartesian Therapeutics Amidst Promising Clinical Advancements and Strategic Positioning
H.C. Wainwright Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $54
H.C. Wainwright analyst Mitchell Kapoor maintains $Cartesian Therapeutics(RNAC.US)$ with a buy rating, and maintains the target price at $54.According to TipRanks data, the analyst has a success rate
Cartesian Stock Climbs 8% on FDA Regenerative Therapy Designation
Express News | Cartesian Therapeutics Shares up 8.3% on Fda's 'rmat' Tag for Autoimmune Disorder Treatment
No Data
T-24Century : looking good hehe
T-24Century : they add around 12m shares and the float is now at 280m from 55m before de added shares.
TrytosaveabitOP T-24Century: I think they have that wrong?
T-24Century : how can you calculate the math?
the price should be maybe 38 -40?
TrytosaveabitOP T-24Century: That depends! Some calculate the market cap using shares in lockup and unregistered shares? Me I just use the price it’s trading at times the number of shares that are available for trading! That’s the difference between Float Market cap and Full Market Capitalization! Hope this help?
View more comments...